Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....

Full description

Bibliographic Details
Main Authors: Donger Zhang, Xia Li, Jing Ding, Xiatong Ke, Wenpei Ding, Yinan Ren, He Xu, Hongchao Li, Aixia Ma, Wenxi Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Public Health
Subjects:
value
perampanel
cost-effectiveness
budget impact
epilepsy
partial-onset seizures
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2021.670108/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2021.670108/full

Similar Items